Related Experiment Videos
Clinical features and management of cystinuria
Insights
Cystinuria, a hereditary kidney stone disease, is managed with increased fluid and alkali intake. D-penicillamine may dissolve stones but has risks, requiring careful use alongside other treatments.
Area of Science:
- Nephrology
- Urology
- Genetics
Background:
- Cystinuria is a hereditary disorder affecting kidney stone formation.
- It impacts both sexes equally, with symptoms often appearing in childhood or young adulthood.
- Hyperuricemia is a common associated finding, likely multifactorial.
Purpose of the Study:
- To outline the management of cystinuria, focusing on medical treatment strategies.
- To discuss the efficacy and risks of D-penicillamine in treating cystine urolithiasis.
Main Methods:
- Review of existing literature and clinical guidelines for cystinuria management.
- Analysis of treatment outcomes with fluid therapy, alkalinization, and D-penicillamine.
Main Results:
- Prophylactic use of oral fluids and alkali is effective in stone-free patients.
- Dissolving existing stones typically requires additional treatment, such as D-penicillamine.
- D-penicillamine aids stone dissolution and prevents recurrence but carries risks of severe toxic reactions.
Conclusions:
- Optimal cystinuria management involves adequate oral fluids and alkali, especially prophylactically.
- D-penicillamine is a valuable adjunct for stone dissolution and prevention in specific cases.
- Physicians should consider complicating factors if standard therapy fails.
Abstract:
Cystinuria is a complex hereditary disorder that affects both sexes with equal frequency and severity. Symptoms usually begin early (children and young adults) but may develop at any age. Stature is normal and there are no clinical nutritional abnormalities. The morbidity of cystine urolithiasis is considerable. Hyperuricemia is a frequent associated finding and is probably the result of multiple factors. No other abnormalities are consistently related to this disease. Treatment with adequate oral fluids to ensure a copious urine volume and with oral alkali to keep the urine alkaline is most successful when used prophylactically in the stone-free patient. However, dissolution of existing calculi is unlikely with this regimen alone. The addition of D-penicillamine often results in dissolution of stones and prevention of recurrent calculi in patients who have continued stone growth despite the use of oral fluids and alkali. Because toxic reactions with D-penicillamine are frequent and sometimes severe, this drug should be used only when necessary and then as an adjunct to rather than a substitute for increased oral fluids and alkali. Failure of treatment in spite of adequate therapy should alert the physician to the possibility of coexisting complicating problem.